<DOC>
	<DOCNO>NCT00004220</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness oxaliplatin gemcitabine treat patient advanced cancer .</brief_summary>
	<brief_title>Oxaliplatin Gemcitabine Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose dose limit toxicity gemcitabine combination oxaliplatin patient advanced malignancy . II . Determine pharmacokinetics oxaliplatin gemcitabine patient . OUTLINE : This multicenter , dose escalation study gemcitabine . Patients receive oxaliplatin IV 2 hour day 1 gemcitabine IV 30 minute day 1 8 . Treatment continue every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos gemcitabine combination fix dose oxaliplatin maximum tolerate dose ( MTD ) determine . The MTD define dose 1 6 patient experience dose limit toxicity . PROJECTED ACCRUAL : A total 24-36 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic unresectable malignancy standard therapy exist longer effective No great 3 prior treatment regimens No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : At least 2 month Hematopoietic : WBC least 3000/mm3 Absolute neutrophil count least 1500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin normal SGOT/SGPT great 2.5 time upper limit normal Renal : Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other : No clinically significant neuropathy Not pregnant nursing Fertile patient must use effective contraception No allergy platinum compound antiemetic No uncontrolled active infection illness PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy Endocrine therapy : See Disease Characteristics Radiotherapy : See Disease Characteristics No prior radiotherapy least 30 % bone marrow At least 4 week since prior radiotherapy Surgery : See Disease Characteristics Other : No concurrent investigational agent No concurrent anticancer therapy No HIV positive patient receive antiretroviral therapy ( HAART )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>